Shares Of This Micro Cap Rally On IP Expansion News

Sponsored:

Wednesday, March 12, 2025

Technology patents play a crucial role for innovative companies as they provide exclusive rights to their innovations, allowing the companies to recoup research and development costs, fund further innovation, and maintain a competitive edge in the market.

With that said, it’s no surprise that investors of Biotricity Inc. (OTCQB:BTCY) have been bidding up shares of this Technology-as-a-Service (Taas) company on the announcement that they expanded their intellectual property (IP) portfolio with 14 new patents.

Biotricity, Inc. specializes in cutting-edge diagnostic and chronic disease management solutions for healthcare providers and consumers. This IP expansion brings the company’s total to 15 issued patents, with an additional 14 patents pending. By streamlining diagnostic processes, Biotricity helps medical providers detect potential health issues earlier, improving patient outcomes while also reducing the burden on the stressed healthcare system.

Biotricity’s newest group of patents represents a breakthrough in remote patient monitoring technology, with a focus on multi-sensor patch devices capable of collecting various biometrics. These innovations are centered on a versatile device platform with base components that can be inserted into a patch form factor, then removed and placed into a watch form factor. This adaptable design ensures wider integration and compliance for different patient needs and clinical applications.

This group of patents will drive Biotricity’s next-generation device which could enable multiple diagnostic studies to be conducted simultaneously. For instance, patients needing a cardiac and sleep study would traditionally have to navigate fragmented care pathways, schedule multiple appointments, and endure long wait times. With Biotricity, these critical diagnostic assessments could be performed concurrently with the same device, reducing delays in diagnosis and expediting treatment.

“At Biotricity, we believe that the future of patient care lies in the ability to monitor and manage individuals from the comfort of their home.” said Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity. “Our solutions deliver actionable data to healthcare providers, facilitating quicker intervention to improve patient outcomes while driving revenue through insurance reimbursement.”

This IP expansion announcement has sent shares of BTCY up 13.23% to $0.60 in mid-morning trading.

Sponsored: